✦ LIBER ✦

390 A phase I trial of weekly AP23573, a novel mTOR inhibitor, in patients with advanced or refractory malignancies: a pharmacokinetic (PK) and pharmacodynamic (PD) analysis

✍ Scribed by A.A. Desai; L. Janisch; L. Berk; H.L. Knowles; V.M. Rivera; H.L. Kindler; W.M. Stadler; C.L. Bedrosian; M.J. Ratain

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

409 AP23573, an mTOR inhibitor, administ

✍ M. Mita; E. Rowinsky; A. Mita; S. Syed; Q. Chu; M. Goldston; H. Knowles; V. Rive 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 149 KB

706 POSTER A phase I dose escalation pha

✍ S. Chia; K. Chi; C. Kollmannsberger; K. Paton; K. Bhagat; S. D'Aloisio; A. Das-G 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 66 KB

83 POSTER A phase I study examining week

✍ M. Mita; J. Cooper; A. Ricart; A. Mita; C. Takimoto; S. Britt; A. Tolcher; A. Do 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 60 KB

374 Clinical, pharmacokinetic (PK) and p

✍ A. Awada; N. Houedé; J.P. Delord; M. Dubuisson; A. Italiano; Y. Bergé; S. Faivre 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 46 KB

365 First-in-human, safety, pharmacodyna

✍ J.C. Soria; U. Banerji; R. Bahleda; M. Martinez Garcia; S. Dolly; L. Lee; R. Rue 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 63 KB

554 POSTER Pharmacokinetic (PK) and phar

✍ M.L. Rothenberg; E. Poplin; P. LoRusso; E. Yu; J. Schwartz; F. Fox; J. Mehnert; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 73 KB